Clinical Trials
17 trialsNCT04354246 2026-05-12
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Phase 1 Completed
NCT05974150 2026-02-23
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Carevive Systems, Inc.
Recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT01931644 2024-04-18
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Completed
NCT04025216 2024-01-24
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
Phase 1 Terminated
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT00531284 2017-08-15
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
Phase 1/2 Completed
NCT02303353 2017-02-24
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
SPGO Research Mannheim GmbH
Unknown
NCT00948961 2016-06-27
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Phase 1/2 Completed
NCT01459653 2016-01-11
Monitor-GCSF
Sandoz
Completed
NCT00270166 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00475956 2010-04-15
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed